

Cytosorbents Corp  
Form 8-K  
January 11, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): January 11, 2016

**CYTOSORBENTS CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware**

**000-51038**

**98-0373793**

(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

**7 Deer Park Drive, Suite K,**

**Monmouth Junction, New Jersey**

**08852**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (732) 329-8885

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD.**

On January 11, 2016, officers of CytoSorbents Corporation, a Delaware corporation (the “Company”) presented at the Biotech Showcase™ 2016 conference. The Company’s presentation is furnished as Exhibit 99.1 hereto.

On January 11, 2016, the Company issued a letter to its stockholders summarizing the Company’s achievements in 2015 and the Company’s goals for 2016. The stockholder letter is furnished as Exhibit 99.2 hereto.

The information in this Form 8-K (including the Exhibits) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by referenced in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific referenced in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
------------------------	--------------------

- |      |   |
|------|---|
| 99.1 | Biotech Showcase™ 2016 conference presentation, January 11, 2016. |
| 99.2 | Stockholder letter issued on January 11, 2016.                    |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 11, 2016 CYTOSORBENTS CORPORATION

By: /s/ Dr. Phillip P. Chan  
Name: Dr. Phillip P. Chan  
Title: President and Chief Executive Officer